miR-21表达与胃癌细胞阿帕替尼敏感性关系的实验研究

被引:2
作者
谭亭昭
吴超
王媛
申振涛
机构
[1] 聊城市传染病医院肿瘤内科
关键词
胃癌; microRNA; 阿帕替尼; 敏感性; 血管生成;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
目的探讨miR-21表达与胃癌细胞对阿帕替尼敏感性的关系以及可能作用机制。方法体外培养人胃癌AGS细胞和耐药AGSAR细胞,分别转染miR-21 inhibitor或miR-21 mimics。采用荧光定量PCR(QPCR)检测AGS和AGSAR细胞miR-21表达水平;QPCR检测不同浓度(0、2、5、10μmol/L)阿帕替尼对AGS和AGSAR细胞p-VEGFR2和p-Akt mRNA表达水平的影响,以及不同miR-21表达对AGS和AGSAR细胞p-VEGFR2、p-Akt、PTEN mRNA表达水平的影响;采用MTT法和划痕实验检测阿帕替尼对AGS、AGSAR细胞增殖和迁移的影响。结果 AGS细胞中miR-21、p-VEGFR2和p-Akt表达量分别为0.82±0.09、0.73±0.09和0.68±0.08,均高于AGSAR的0.35±0.10、0.33±0.07和0.25±0.04,差异有统计学意义(P<0.05);经阿帕替尼处理后,AGSAR细胞的增殖和迁移活性明显高于AGS细胞(P<0.05)。10μmol/L阿帕替尼处理24 h后,阴性对照组AGS细胞的存活率和迁移距离分别为(39.48±7.45)%和(70.44±11.57)μm,明显低于miR-21 inhibitor转染AGS细胞的(80.63±8.27)%和(108.46±10.39)μm,差异有统计学意义(P<0.05);阴性对照组AGSAR细胞存活率和迁移距离(78.82±8.14)%和(93.15±9.86)μm,明显高于miR-21 mimics转染AGSAR细胞的(29.95±6.74)%和(61.43±9.85)μm,差异有统计学意义(P<0.05)。转染miR-21 inhibitor后,AGS细胞中p-VEGFR2和p-Akt mRNA相对表达水平分别为1.12±0.13和0.82±0.10,明显高于阴性对照组的0.73±0.11和0.64±0.11,而PTEN mRNA表达水平则下调(0.18±0.04 vs.0.51±0.08),差异均有统计学意义(P<0.05)。转染miR-21 mimics后,AGSAR细胞p-VEGFR2和p-Akt mRNA相对表达水平分别为0.17±0.04和0.12±0.03,明显低于阴性对照组的0.30±0.04和0.25±0.02,而PTEN mRNA表达水平则上调(0.53±0.06 vs.0.44±0.03),差异均有统计学意义(P<0.05)。结论上调miR-21表达可增加VEGFR-2和Akt磷酸化水平,从而提高胃癌细胞对阿帕替尼的敏感性。
引用
收藏
页码:598 / 603
页数:6
相关论文
共 10 条
[1]   The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab [J].
Eto, Kojiro ;
Iwatsuki, Masaaki ;
Watanabe, Masayuki ;
Ida, Satoshi ;
Ishimoto, Takatsugu ;
Iwagami, Shiro ;
Baba, Yoshifumi ;
Sakamoto, Yasuo ;
Miyamoto, Yuji ;
Yoshida, Naoya ;
Baba, Hideo .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (01) :343-350
[2]  
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer:Case Report and Review of Literature. Ding L,Li QJ,You KY,Jiang ZM,Yao HR. Medicine Baltimore . 2016
[3]   microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN [J].
Zhang, Bao Gui ;
Li, Jian Fang ;
Yu, Bei Qin ;
Zhu, Zheng Gang ;
Liu, Bing Ya ;
Yan, Min .
ONCOLOGY REPORTS, 2012, 27 (04) :1019-1026
[4]  
Association of microRNA Polymorphisms with the Risk of Gastric Cancer in a Romanian Population. Rogoveanu I,Burada F,Cucu MG,et al. J Gastrointestin Liver Dis . 2017
[5]  
Urine mi R-21-5p as a potential non-invasive biomarker for gastric cancer. Kao HW,Pan CY,Lai CH,et al. Oncotarget . 2017
[6]  
Cancer statistics in China, 2015[J] . Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He. &nbspCA: A Cancer Journal for Clinicians . 2016 (2)
[7]   阿帕替尼治疗胃癌的临床应用专家共识 [J].
秦叔逵 ;
李进 .
临床肿瘤学杂志, 2015, 20 (09) :841-847
[8]  
Role of microRNAs in gastric cancer[J]. Hideyuki Ishiguro,Masahiro Kimura,Hiromitsu Takeyama.  World Journal of Gastroenterology. 2014(19)
[9]  
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Roviello G,Petrioli R,Marano L,et al. Gastric Cancer . 2016
[10]  
Apatinib for chemotherapy-refractory advancedmetastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm,phase II trial. Li J,Qin S,Xu J, et al. Journal of Clinical Oncology . 2013